Framing Frontline CLL Treatment Discussions With Patients

Frontline treatment of chronic lymphocytic leukemia (CLL) now centers on a choice between continuous and fixed-duration targeted therapy, and this segment examines how experts frame that choice with patients. The faculty outline the current toolkit, including covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors and venetoclax, and note that chemoimmunotherapy has largely receded from frontline practice. Beyond efficacy, they emphasize practical factors that shape the decision: willingness to attend infusion visits and tumor lysis monitoring, distance from the treating center, out-of-pocket costs, and comorbidities that raise concern about cumulative BTK inhibitor toxicity. The experts consider whether prognostic workup or patient preference more often drives the path chosen, suggesting that patients with high-risk disease may benefit from continuous therapy while acknowledging the evidence is not settled. They close by noting that an expanding range of better-tolerated options may help preserve efficacy while reducing both clinical and financial toxicity, in a disease where life expectancy has largely been normalized.